Acerus Pharmaceuticals Corporation announced that two abstracts highlighting the clinical benefits of NATESTO® were accepted for presentation at the American Urological Association’s (AUA) 2017 Annual Meeting, to be held May 12-16 in Boston. NATESTO® is the first and only testosterone nasal gel available in Canada and the US indicated for androgen replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). The following summarizes the two abstracts accepted for presentation at the AUA’s 2017 Annual Meeting: NATESTO® is a testosterone nasal gel developed by Acerus Pharmaceutical Corporation and indicated as a replacement therapy for men diagnosed with conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). It is the first and only nasally-administered testosterone product approved by the U.S. FDA and Health Canada, and available in a ‘no-touch’ dispenser with a metered dose pump for reduced transference risk The recommended starting dose of NATESTO® in Canada is 11 mg of testosterone (one actuation per nostril) administered twice daily for a total daily dose of 22 mg.